Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 17;9(7):418.
doi: 10.3390/antibiotics9070418.

Narrow-Spectrum Antibacterial Agents-Benefits and Challenges

Richard A Alm  1 , Sushmita D Lahiri  2
Affiliations

Narrow-Spectrum Antibacterial Agents-Benefits and Challenges

Richard A Alm et al. Antibiotics (Basel). .

Abstract

The number of antibacterial agents in clinical and preclinical development possessing activity against a narrow spectrum of bacterial pathogens is increasing, with many of them being nontraditional products. The key value proposition hinges on sparing antibiotic use and curtailing the emergence of resistance, as well as preventing the destruction of a beneficial microbiome, versus the immediate need for effective treatment of an active infection with a high risk of mortality. The clinical use of a targeted spectrum agent, most likely in combination with a rapid and robust diagnostic test, is a commendable goal with significant healthcare benefits if executed correctly. However, the path to achieving this will come with several challenges, and many scientific and clinical development disciplines will need to align their efforts to successfully change the treatment paradigm.

Keywords: antibacterial; diagnostics; narrow-spectrum; nontraditional; research and development.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ardal C., Findlay D., Savic M., Carmeli Y., Gyssens I., Laxminarayan R., Outterson K., Rex J.H. Innovative Medicines Initiative DRIVE-AB Report. Revitalizing the Antibiotic Pipeline: Stimulating Innovation while driving Sustainable Use and Global Access. [(accessed on 31 May 2020)];2018 Available online: http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Final-Report-Jan2....
    1. Mullard A. Achaogen bankruptcy highlights antibacterial development woes. Nat. Rev. Drug Discov. 2019;18:411–412. doi: 10.1038/d41573-019-00085-w. - DOI - PubMed
    1. Roland D. Antibiotic Makers Struggle, Hurting War on Superbugs. [(accessed on 31 May 2020)];2019 Available online: https://www.wsj.com/articles/antibiotic-makers-find-rewards-for-tackling....
    1. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., Satta G., Cooke G., Holmes A. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin. Infect. Dis. 2020:ciaa530. doi: 10.1093/cid/ciaa530. - DOI - PMC - PubMed
    1. World Health Organization Record Number of Countries Contribute Data Revealing Disturbing Rates of Antimicrobial Resistance. [(accessed on 6 June 2020)];2020 Available online: https://www.who.int/news-room/detail/01-06-2020-record-number-of-countri....

LinkOut - more resources